Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Clear Route II

As this week's cover story reports, executives of the next class of IPOs are building new investment stories based on more hard-bitten realism about investor demands for realistic valuations, clinical progress and portfolio breadth.

These are the kinds of stories we advocated in December, when BioCentury offered The Clear Route to ROI as a management model for the creation of shareholder value. In a nutshell, investors are keeping valuations low until risk is wrung out of a stock. The challenge to companies is to alter investor perceptions of the risk/reward ratio so that they invest now, rather than later.

Read the full 983 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE